Biosimilars Illuminating the Future of Ophthalmology Treatments In 2023

Ophthalmology has witnessed significant advancements in recent years. Among these developments, biosimilars have emerged as a promising avenue, providing increased access to effective and affordable treatments for various ophthalmic conditions.

Ophthalmic diseases, such as age-related macular degeneration (AMD), diabetic macular edema (DME), and various inflammatory conditions, often require long-term treatment with biologic medications. Biosimilars provide an opportunity to expand treatment options, increase competition, and lower costs in ophthalmology. By offering similar efficacy and safety profiles at a reduced price, biosimilars can enhance accessibility to biologic therapies for a larger patient population.

The treatment of neovascular age-related macular degeneration myopic choroidal neovascularization, and macular edoema following retinal vein blockage are all conditions for which Byooviz® (ranibizumab-nuna) is the first biosimilar to earn FDA clearance. According to BioIntel360, the United States biosimilar market size is expected to record a CAGR of 30.7% during 2023-2027 to reach US$11,316.0 million by 2027, increasing from US$3,879.6 million in 2023. Over the last five years, the sector has recorded a CAGR of 30.5%. Aflibercept and bevacizumab biosimilar drugs for eye illness are two other ones that are being developed and have licencing processes in the US.

According to a statement issued by Samsung Bioepis, the Phase 3 research findings for SB15, a potential biosimilar to Eylea1 (aflibercept), were recently presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which took place from April 23 to 27 in New Orleans, Louisiana. New analytical information was also presented about the structural, physicochemical, and biological similarities between SB15 and the reference product.
At the symposium, researchers presented 56-week outcomes from the Phase 3 clinical study contrasting SB15 to the reference drug aflibercept (AFL) in terms of efficacy, safety, immunogenicity, and pharmacokinetics (PK).
The identical Phase 3 study's 32-week intermediate results were previously reported at the American Academy of Ophthalmology (AAO) Annual Meeting in 2022.
For two ophthalmology biosimilar prospects, SB11/BYOOVIZTM (ranibizumab) and SB15 (aflibercept), Samsung Bioepis and Biogen stated in November 2019 that they were entering into a joint commercialization agreement for these two products in key international markets.
If passed, SB15 will expand the alternatives available to patients and prescribers while supporting the sustainability of healthcare by enhancing the portfolio capabilities of the two companies that provide two of the most often prescribed anti-VEGF treatments.

The development and approval of biosimilars in ophthalmology follow a rigorous scientific and regulatory process. Extensive comparative studies, including analytical, preclinical, and clinical evaluations, are conducted to establish similarity with the reference product. Clinical trials involving patients with ophthalmic conditions are designed to demonstrate comparable efficacy, safety, and immunogenicity profiles. Regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency have established robust guidelines specific to biosimilar development, ensuring high standards of quality, safety, and efficacy.

Biosimilar provide more affordable treatment options, reducing the financial burden on patients and healthcare systems. This expanded access enables a broader population to benefit from biologic therapies, leading to improved clinical outcomes. With the entry of biosimilar into the market, competition intensifies, leading to price reductions for both originator biologics and biosimilar. These cost savings have the potential to positively affect healthcare budgets and enable the allocation of resources to other critical areas.

The American Academy of Ophthalmology is aware of the potential social benefits that biosimilars could have in terms of enhancing the treatment of individuals with eye diseases. Before biosimilars are frequently advised for use in ophthalmology, there should be enough evidence of their safety and efficacy for treating eye illnesses. When employed, the treating ophthalmologist and their patient should decide which biologic product—reference, biosimilar, or interchangeable—to use. Bevacizumab has been successfully and affordably used off-label for eye disease for over 15 years, which marks a rare history of a thoroughly researched biologic product injected into the eye and which has not yet been replicated by bevacizumab biosimilars. The availability of biosimilar promotes sustainability in healthcare by controlling escalating treatment costs. It allows healthcare providers to allocate resources more effectively, ensuring a wider range of patients can access necessary ophthalmic treatments.

BioIntel360 suggests that biosimilars will play an important role in the field of ophthalmology by expanding treatment options, improving accessibility, and promoting competition and with a well-established regulatory pathway and robust clinical evidence, biosimilars offer a viable alternative to expensive drugs.